<table id="L9dfeee57-c500-4293-991e-9d28ff9be289" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><caption>Table 1. Patient Responses at 3-Month Post-Second Treatment Session</caption>
<colgroup>
<col width="31%"></col>
<col width="18%"></col>
<col width="14%"></col>
<col width="20%"></col>
<col width="16%"></col>
</colgroup>
<thead>
<tr><td></td><td align="center" colspan="2">Australian Study</td><td align="center" colspan="2">U. S. Study</td></tr>
<tr><td>Patient Response</td><td align="center">Metvixia-PDT</td><td align="center">Vehicle PDT</td><td align="center">Metvixia -PDT</td><td align="center">Vehicle PDT</td></tr>
</thead>
<tbody>
<tr><td>Patients with at least 75% of AK Lesions Cleared</td><td align="center">
												76/88 (86%)</td><td align="center">
												4/23 (17%)</td><td align="center">
												35/42 (83%)</td><td align="center">
												12/38 (32%)</td></tr>
<tr><td>Complete Responders (All Lesions clinically cleared at 3 months)</td><td align="center">
												71/88 (81%)</td><td align="center">
												3/23 (13%)</td><td align="center">				33/42 (79%)</td><td align="center">
												8/38 (21%)</td></tr>
</tbody>
</table>